Idronoxil

DB04915InvestigationalSmall molecule

Idronoxil is a substance that is being studied in the treatment of cancer. It belongs to the family of drugs called signal transduction inhibitors.

Mechanism: The antiproliferative effects of phenoxodiol are associated with inhibition of plasma membrane electron transport in tumour cell lines and primary immune cells. Results from one study (PMID: 17904534) indicate that plasma membrane electron transport (PMET) may be a primary target for phenoxodiol in tumour cells and in activated T cells.
Curator reviewed
Primary indication: Intended for the treatment of various forms of cancer.Curator reviewed
Formula / weight: C₁₅H₁₂O₃ · 240.254 g/mol (avg)
Also known as: (+/-)-cis-3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-3,4-dihydro-2H-cromen-7-ol · Dehydroequol · Haginin E · Phenoxodiol
Code names: NOX-66 · NV-06

Resolves to

Compound

Structure

InChIKeyZZUBHVMHNVYXRR-UHFFFAOYSA-NSMILESOC1=CC=C(C=C1)C1=CC2=C(OC1)C=C(O)C=C2

Targets

What you can answer from here — as of January 29, 2025

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

12Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Idronoxil, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.